African Americans Carry More Unclassified FH Gene Variants That Still Raise Heart Attack Risk
A large genome-first study reveals critical gaps in familial hypercholesterolemia diagnosis for people of African ancestry due to variant classification bias.
Summary
Familial hypercholesterolemia (FH) is a genetic condition causing dangerously high LDL cholesterol and early heart attacks. Most research has focused on people of European ancestry, leaving other groups understudied. This large study of over 104,000 African ancestry individuals found that FH-causing gene variants are just as common across ancestries, but African ancestry individuals are far more likely to carry variants labeled 'unknown significance' — yet these variants still dramatically raise LDL and heart attack risk. This matters enormously: people carrying these under-classified variants may be going undiagnosed and untreated. The findings point to a systemic flaw in genetic databases that have been built primarily on European data, suggesting that current tools may be failing non-European patients at scale.
Detailed Summary
Familial hypercholesterolemia (FH) is one of the most common inherited cardiovascular disorders, characterized by lifelong elevated LDL cholesterol and a markedly increased risk of premature heart attacks. Despite its prevalence, the scientific literature on FH has been dominated by studies of European-ancestry populations, raising concerns that diagnostic tools and variant databases may not work equally well across all ancestries.
This genome-first study examined more than 104,300 African ancestry individuals enrolled across three major US biobanks — the NIH's All of Us, Mount Sinai's BioMe, and Geisinger's MyCode — comparing genetic FH findings and clinical outcomes against European ancestry participants from the same cohorts.
The prevalence of confirmed pathogenic FH variants was similar between African and European ancestry groups (roughly 1 in 306 vs. 1 in 273). However, African ancestry individuals were 61% more likely to carry a variant of unknown significance (VUS) — a genetic change that cannot currently be classified as harmful or benign. Critically, these VUSs were associated with LDL elevations of over 10 mg/dL and nearly doubled the odds of myocardial infarction among African ancestry individuals, a risk level equivalent to carrying a confirmed pathogenic variant.
These findings expose a fundamental inequity: current variant classification systems, trained predominantly on European genetic data, leave a disproportionate share of African ancestry patients in diagnostic limbo. Clinicians may not treat VUS carriers as aggressively, even when their cardiovascular risk is objectively elevated.
For clinicians and health-conscious individuals alike, this study is a wake-up call. Genetic screening for FH should be interpreted cautiously in non-European patients, and clinical indicators like LDL levels and family history must carry greater weight. Expanding diverse genetic reference databases is urgently needed to close this diagnostic gap.
Key Findings
- FH pathogenic variant prevalence was similar across ancestries: ~1 in 306 African vs. 1 in 273 European individuals.
- African ancestry individuals were 61% more likely to carry a variant of unknown significance (VUS) than European counterparts.
- VUSs in African ancestry individuals raised LDL by ~10 mg/dL and nearly doubled myocardial infarction risk.
- VUS-associated heart attack risk in African ancestry equaled that of confirmed pathogenic variants — a critical diagnostic blind spot.
- Heavy reliance on European-derived variant databases likely leads to systematic underdiagnosis of FH in African ancestry patients.
Methodology
This genome-first study analyzed genetic and clinical data from 104,300+ African ancestry individuals across three US biobanks (All of Us, BioMe, MyCode). Variants were classified per Clinical Genome Resource FH Expert Panel standards; ancestry was assigned by genetic similarity to reference populations. Results were meta-analyzed across cohorts with adjustment for age and sex.
Study Limitations
This summary is based on the abstract only, as the full text was not accessible. The study is observational and cross-sectional in design, limiting causal inference. VUS classification may evolve as databases expand, and findings may not generalize beyond the three US biobank populations studied.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.